flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 🔴Cardiovascular with by severity of chronic disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Kidney Outcomes With Glucagon-Like Peptide-1

A Lithium GLP-1 Interaction More evidence of a serious drug interaction STUDY: Patarroyo-Rodriguez LP et al, J Clin Psychopharmacol 2026 STUDY TYPE: Case report FUNDING: National Center for Advancing Translational Science (NCATS) Background GLP-1 and GIP/GLP-1 receptor agonists like tirzepatide (Mounjaro, Zepbound) cause nausea, vomiting, and dehydration, especially during dose escalation

Insulin Sensitivity Big falls in fasting insulin (up to 70.9% at 48 weeks) indicate significant increases in insulin sensitivity

Bring photographs if possible, as skin findings may not be present during your visit

Your health will still benefit if you eat quality foods and exercise, says Dr

Wilson disease is caused by a genetic defect that allows copper to accumulate in the liver and other organs